SPR-210 targeted monoclonal antibody (Respana therapeutics)

N/A

Report date: 2025/03/20 14:40:07

Base Information

Drug NameSPR-210 targeted monoclonal antibody (Respana therapeutics)
Drug Alias NameN/A
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody
Mechanisms of ActionUnconventional myosin-XVIIIa modulators
TargetsUnconventional myosin-XVIIIa
Therapy Area/IndicationsInfluenza, Human
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesRespana Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesRespana Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsInfluenza, Human
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A